Eccles S A, Modjtahedi H, Box G, Court W, Sandle J, Dean C J
Section of Immunology, Institute of Cancer Research, Sutton, UK.
Invasion Metastasis. 1994;14(1-6):337-48.
Overexpression of members of the type 1 receptor tyrosine kinase (c-erbB) family has been documented in many types of cancer. In the case of c-erbB1 (epidermal growth factor receptor) and c-erbB2, this has been closely linked with poor prognosis, and in particular is apparently associated with an invasive/metastatic phenotype and relative insensitivity to conventional therapies. The cell surface location of these molecules renders them attractive targets for a variety of immunotherapeutic strategies, some of which are showing promise in preclinical and early clinical trials.
1型受体酪氨酸激酶（c-erbB）家族成员的过表达已在多种癌症中得到证实。就c-erbB1（表皮生长因子受体）和c-erbB2而言，这与预后不良密切相关，尤其是明显与侵袭性/转移表型以及对传统疗法相对不敏感有关。这些分子的细胞表面定位使其成为多种免疫治疗策略的有吸引力的靶点，其中一些在临床前和早期临床试验中显示出前景。
